Podocalyxin Antibody (Human, Monoclonal)

Description

Podocalyxin Antibody (Human, Monoclonal)
Catalog number: B2010423
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 0.1 mg
Molecular Weight or Concentration: 150 kDa
Supplied as: Liquid
Appearance: Liquid Solution
Applications: Mouse monoclonal Antibody to human Podocalyxin, a sialoglycoprotein related to CD34.
Storage: -20C
Keywords: GCTM-2, Gp200, Podocalyxin-like protein 1
Grade: Biotechnology grade. All solid components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Akankwasa G, Jianhua L, Guixue C, Changjuan A, Xiaosong Q. Urine markers of
podocyte dysfunction: a review of podocalyxin and nephrin in selected glomerular
diseases. Biomark Med. 2018 Aug;12(8):927-935.

2: Imaizumi T, Nakatochi M, Akiyama S, Yamaguchi M, Kurosawa H, Hirayama Y,
Katsuno T, Tsuboi N, Hara M, Maruyama S. Urinary Podocalyxin as a Biomarker to
Diagnose Membranous Nephropathy. PLoS One. 2016 Sep 26;11(9):e0163507.

3: Tamayo-Orbegozo E, Amo L, Díez-García J, Amutio E, Riñón M, Alonso M, Arana
P, Maruri N, Larrucea S. Emerging Role of Podocalyxin in the Progression of
Mature B-Cell Non-Hodgkin Lymphoma. Cancers (Basel). 2020 Feb 8;12(2):396.

4: Nielsen JS, McNagny KM. The role of podocalyxin in health and disease. J Am
Soc Nephrol. 2009 Aug;20(8):1669-76.

5: Toyoda H, Nagai Y, Kojima A, Kinoshita-Toyoda A. Podocalyxin as a major
pluripotent marker and novel keratan sulfate proteoglycan in human embryonic and
induced pluripotent stem cells. Glycoconj J. 2017 Dec;34(6):817-823.

6: Toyoda H, Nagai Y, Kojima A, Kinoshita-Toyoda A. Podocalyxin as a major
pluripotent marker and novel keratan sulfate proteoglycan in human embryonic and
induced pluripotent stem cells. Glycoconj J. 2017 Apr;34(2):139-145.

7: Schopperle WM, DeWolf WC. The TRA-1-60 and TRA-1-81 human pluripotent stem
cell markers are expressed on podocalyxin in embryonal carcinoma. Stem Cells.
2007 Mar;25(3):723-30.

8: Wong BS, Shea DJ, Mistriotis P, Tuntithavornwat S, Law RA, Bieber JM, Zheng
L, Konstantopoulos K. A Direct Podocalyxin-Dynamin-2 Interaction Regulates
Cytoskeletal Dynamics to Promote Migration and Metastasis in Pancreatic Cancer
Cells. Cancer Res. 2019 Jun 1;79(11):2878-2891.

9: Rolnik DL, Wang Y, Hyett J, Silva Costa FD, Nie G. Serum podocalyxin at 11-13
weeks of gestation in the prediction of small for gestational age neonates. J
Perinatol. 2019 Jun;39(6):784-790.
10: Kostovska I, Trajkovska KT, Cekovska S, Topuzovska S, Kavrakova JB,
Spasovski G, Kostovski O, Labudovic D. Role of urinary podocalyxin in early
diagnosis of diabetic nephropathy. Rom J Intern Med. 2020 Dec 17;58(4):233-241.

Products Related to Podocalyxin Antibody (Human, Monoclonal) : Antibodies